Keith Lenden, Board Director

Venture Partner, ARCH Ventures

Keith Lenden joined ARCH Venture Partners in 2017 as a Venture Partner.  Keith is a seasoned entrepreneur and leader in the biotechnology and pharmaceutical industries with a proven track record in company formation, executive and project leadership, corporate development and product and market strategy. Keith is a co-founder of Autobahn Therapeutics, Inc., a CNS-focused thyroid hormone biology and drug development company, Boundless Bio, Inc., an ecDNA cancer biology and drug discovery company, Receptos, Inc., a multiple sclerosis biology and GPCR drug discovery company acquired by Celgene (now BMS), and Abide Therapeutics, Inc., a cannabinoid biology and serine hydrolase drug discovery company acquired by H. Lundbeck A/S.  Keith has served in a wide range of executive and product leadership roles for both public and private biopharmaceutical companies over the years, including Esperion Therapeutics, Inc., Maxygen, Inc., Acologix, Inc. and Genteric, Inc. Keith started his career in biotechnology as a consultant at LEK Consulting.

Keith holds an MBA from the Haas School of Business at the University of California, Berkeley where he was selected as a Price Institute for Entrepreneurial Studies Venture Capital Fellow. Keith also earned A.B. and B.E. degrees from the Thayer School of Engineering at Dartmouth College.  Keith is a Kauffman Fellow where he received the Jeff Timmons Leadership Award.